New exploration of signal detection from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China
CONCLUSIONS: In this study, we attempted a new way to find potential drug risks using small spontaneous reporting data. Our findings also suggested the need for more precise identification of allergic risks and the improvement of traditional Chinese medicine labels.PMID:38009292 | DOI:10.1080/14740338.2023.2288143 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - November 27, 2023 Category: Drugs & Pharmacology Authors: Yuan Liu Xiaoli Xu Jingfei Yang Yuwei Zhang Mengjiao He Wenzhi Liao Na Wang Pengcheng Liu Source Type: research
The real-world safety of sacubitril / valsartan among older adults ( ≥75): A pharmacovigilance study from the FDA data
Heart failure is a major cause of morbidity and mortality among older adults. Sacubitril-Valsartan (Sac/Val) has been shown to improve patients' outcomes; however, its safety profile among older adults has not been adequately examined. We therefore aimed to examine its safety profile among this population. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - November 27, 2023 Category: Cardiology Authors: Tsahi T. Lerman, Noam Greenberg, Boris Fishman, Adam Goldman, Yeela Talmor-Barkan, Bauer Menachem, Idan Goldberg, Elad Goldberg, Ran Kornowski, Ilan Krause, Amos Levi, Eytan Cohen Source Type: research
Irreversible myocardial injury attenuates the benefits of sacubitril/valsartan in heart failure patients
Despite the established benefits of angiotensin receptor-neprilysin inhibitor (ARNI) in heart failure with reduced ejection fraction (HFrEF) across various etiologies, there are controversies regarding the effects of ARNI in patients with irreversible myocardial injury. The aim of this study is to investigate the impact of irreversible myocardial injury on the benefits of ARNI treatment in patients with HFrEF, consisted of both ischemic and non-ischemic etiologies. (Source: International Journal of Cardiology)
Source: International Journal of Cardiology - November 27, 2023 Category: Cardiology Authors: Hong-Mi Choi, In-Chang Hwang, Hye Jung Choi, Yeonyee E. Yoon, Hyun-Jung Lee, Jun-Bean Park, Seung-Pyo Lee, Hyung-Kwan Kim, Yong-Jin Kim, Goo-Yeong Cho Source Type: research
Relevant adverse events and drug discontinuation of Sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry
CONCLUSION: In Japan, sacubitril/valsartan was also prescribed to patients not eligible for landmark trials, and AEs were observed at a relatively high rate from soon after treatment initiation. Physicians should closely monitor patients for these events, especially in patients anticipated to have a higher risk of AEs.PMID:38000538 | DOI:10.1016/j.jjcc.2023.11.005 (Source: Journal of Cardiology)
Source: Journal of Cardiology - November 24, 2023 Category: Cardiology Authors: Shingo Matsumoto John J V McMurray Takahito Nasu Shunsuke Ishii Nobuyuki Kagiyama Keisuke Kida Wataru Fujimoto Atsushi Kikuchi Takeshi Ijichi Tatsuhiro Shibata Takanori Ikeda Koshiro Kanaoka Source Type: research
Relevant adverse events and drug discontinuation of Sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry
CONCLUSION: In Japan, sacubitril/valsartan was also prescribed to patients not eligible for landmark trials, and AEs were observed at a relatively high rate from soon after treatment initiation. Physicians should closely monitor patients for these events, especially in patients anticipated to have a higher risk of AEs.PMID:38000538 | DOI:10.1016/j.jjcc.2023.11.005 (Source: Journal of Cardiology)
Source: Journal of Cardiology - November 24, 2023 Category: Cardiology Authors: Shingo Matsumoto John J V McMurray Takahito Nasu Shunsuke Ishii Nobuyuki Kagiyama Keisuke Kida Wataru Fujimoto Atsushi Kikuchi Takeshi Ijichi Tatsuhiro Shibata Takanori Ikeda Koshiro Kanaoka Source Type: research
Relevant adverse events and drug discontinuation of Sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry
CONCLUSION: In Japan, sacubitril/valsartan was also prescribed to patients not eligible for landmark trials, and AEs were observed at a relatively high rate from soon after treatment initiation. Physicians should closely monitor patients for these events, especially in patients anticipated to have a higher risk of AEs.PMID:38000538 | DOI:10.1016/j.jjcc.2023.11.005 (Source: Journal of Cardiology)
Source: Journal of Cardiology - November 24, 2023 Category: Cardiology Authors: Shingo Matsumoto John J V McMurray Takahito Nasu Shunsuke Ishii Nobuyuki Kagiyama Keisuke Kida Wataru Fujimoto Atsushi Kikuchi Takeshi Ijichi Tatsuhiro Shibata Takanori Ikeda Koshiro Kanaoka Source Type: research
Relevant adverse events and drug discontinuation of Sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry
CONCLUSION: In Japan, sacubitril/valsartan was also prescribed to patients not eligible for landmark trials, and AEs were observed at a relatively high rate from soon after treatment initiation. Physicians should closely monitor patients for these events, especially in patients anticipated to have a higher risk of AEs.PMID:38000538 | DOI:10.1016/j.jjcc.2023.11.005 (Source: Journal of Cardiology)
Source: Journal of Cardiology - November 24, 2023 Category: Cardiology Authors: Shingo Matsumoto John J V McMurray Takahito Nasu Shunsuke Ishii Nobuyuki Kagiyama Keisuke Kida Wataru Fujimoto Atsushi Kikuchi Takeshi Ijichi Tatsuhiro Shibata Takanori Ikeda Koshiro Kanaoka Source Type: research
Relevant adverse events and drug discontinuation of Sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry
CONCLUSION: In Japan, sacubitril/valsartan was also prescribed to patients not eligible for landmark trials, and AEs were observed at a relatively high rate from soon after treatment initiation. Physicians should closely monitor patients for these events, especially in patients anticipated to have a higher risk of AEs.PMID:38000538 | DOI:10.1016/j.jjcc.2023.11.005 (Source: Journal of Cardiology)
Source: Journal of Cardiology - November 24, 2023 Category: Cardiology Authors: Shingo Matsumoto John J V McMurray Takahito Nasu Shunsuke Ishii Nobuyuki Kagiyama Keisuke Kida Wataru Fujimoto Atsushi Kikuchi Takeshi Ijichi Tatsuhiro Shibata Takanori Ikeda Koshiro Kanaoka Source Type: research
Relevant adverse events and drug discontinuation of Sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry
CONCLUSION: In Japan, sacubitril/valsartan was also prescribed to patients not eligible for landmark trials, and AEs were observed at a relatively high rate from soon after treatment initiation. Physicians should closely monitor patients for these events, especially in patients anticipated to have a higher risk of AEs.PMID:38000538 | DOI:10.1016/j.jjcc.2023.11.005 (Source: Journal of Cardiology)
Source: Journal of Cardiology - November 24, 2023 Category: Cardiology Authors: Shingo Matsumoto John J V McMurray Takahito Nasu Shunsuke Ishii Nobuyuki Kagiyama Keisuke Kida Wataru Fujimoto Atsushi Kikuchi Takeshi Ijichi Tatsuhiro Shibata Takanori Ikeda Koshiro Kanaoka Source Type: research
Functional changes in the heart after sacubitril/valsartan use in 5 hemodialysis patients with hypertension. Case report
In conclusion, 5 patients had hypertension, including 2 patients with heart failure. Sacubitril/valsartan improved blood pressure post-dialysis, heart failure symptoms, NT-pro- BNP, the left atrial dim ension, the left ventricular ejection fraction, and E/e’, E/A found via echocardiography for a 6-months period. Treatment with sacubitril/valsartan was effective in hemodialysis patients in the cardiac function. (Source: CEN Case Reports)
Source: CEN Case Reports - November 23, 2023 Category: Urology & Nephrology Source Type: research
